Skip to main content
Caplight Logo









AGS Therapeutics

AGS Therapeutics

Private
ParisHealthcare & Life Scienceshttps://www.ags-tx.com/

Last Round

Accelerator

May 30, 2023

Company Overview

AGS Therapeutics is a biotechnology company that utilizes the natural machinery of microalgae to develop therapeutics such as mRNA, RNAi, proteins and peptides, delivered by microalgae extracellular vesicles.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Pharma Supply Chain

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

microalgae extracellular vesiclesMEVsdrug delivery platformextracellular vesiclesplant-derived exosomesalgae-based drug deliverymRNA deliverynon-viral vectorsiRNA deliveryLNP alternativeCDMO servicescontract development and manufacturingCDMObiomanufacturingoral drug deliveryophthalmic drug deliverygene therapy deliveryinflammatory bowel disease

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

AGS Therapeutics Comparables

Compare AGS Therapeutics with similar companies based on industry and business-model similarity.

AGS Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Ciloa
83%
Carmine Therapeutics
82%
Carus Bio
81%

AGS Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
AcceleratorMay 30, 2023
Series ADec 14, 2022
GrantJul 7, 2022
Pre SeedSep 7, 2021

AGS Therapeutics Investors

Notable investors and investment history

AGS Therapeutics investors
InvestorRounds
Government of FranceGrant
Spartners by Servier & BioLabsAccelerator
BpifranceGrant, Pre Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 30, 2023

    Received funding from Sparners by Servier & BioLabs.

  • Dec 14, 2022

    $32M round closed.

AGS Therapeutics Filings

Explore SEC and related filing metadata, where available.

AGS Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about AGS Therapeutics's valuation, stock price, and market status.

Is AGS Therapeutics a public or private company?

AGS Therapeutics is a private company.

What is the current stock price of AGS Therapeutics?

AGS Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is AGS Therapeutics worth (valuation)?

Valuation information for AGS Therapeutics is not publicly available.

Can I buy AGS Therapeutics stock?

AGS Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was AGS Therapeutics's last funding round?

AGS Therapeutics's most recent funding round was Accelerator on May 30, 2023.

Who are the main investors in AGS Therapeutics?

Key investors in AGS Therapeutics include Government of France, Spartners by Servier & BioLabs, Bpifrance.

Will AGS Therapeutics IPO soon?

No public IPO plans have been announced for AGS Therapeutics.

How can I track AGS Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor AGS Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersParis
Year Founded2020
Last FundingMay 30, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?